--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 11, 2001 (September 6, 2001)
BioMarin Pharmaceutical Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-26727 68-0397820
(State or other jurisdiction (Commission (IRS Employer Identification
of incorporation) File Number) No.)
371 Bel Marin Keys Boulevard, 94949
Suite 210 (Zip Code)
Novato, California
(Address of principal
executive offices)
(415) 884-6700
(Registrant's telephone number, including area code)
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Item 5. Other Events
Effective September 6, 2001, Ansbert Gadicke, MD, has resigned from the Board of
Directors of BioMarin. Dr. Gadicke is the Managing Director of MPM Capital LLC
and served as a member of the BioMarin Board of Directors since December 1997.
MPM Capital is the beneficial holder of 3,212,560 shares or 7.6 % of BioMarin's
common stock. The Board elected Phyllis Gardner, MD, Senior Associate Dean for
Education and Student Affairs, Stanford University School of Medicine, to take
Dr. Gadicke's position on the Board.
Item 7. Financial Statements and Exhibits
None
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BioMarin Pharmaceutical Inc.
By: /s/ Raymond W. Anderson
-------------------------------------------------
Raymond W. Anderson
Chief Operating Officer, Chief Financial Officer,
Secretary and Vice President Finance and
Administration
Date: September 11, 2001